

# Medexus Pharmaceuticals Inc

09:32 25 Sep 2020

## Medexus names pharma veteran Michael Pine senior vice president of business development and strategy

Medexus Pharmaceutical Inc (CVE:MDP) (OTCQX:MEDXF) has named pharma executive Michael Pine as its senior vice president of business development and strategy, the company announced Friday.

Pine has experience at both large and small pharmaceutical companies, including work in business development and licensing, M&A, investment banking, business strategy, product marketing US-managed markets and operations.

Most recently, Pine worked as senior vice president of business development and licensing at Lupin Pharmaceuticals. He led that company's efforts to expand its revenue base of more than \$2 billion further into branded and specialty products, with a focus on the North American markets.

### READ: Medexus gets Health Canada nod to market tumor imaging material Gleolan for neurosurgery

Pine has also served in senior roles at companies such as Novartis AG (NYSE:NVS), Kos Pharmaceuticals, Organon Biosciences, Pfizer Inc (NYSE:PFE) and JP Morgan Chase.

"We are pleased to welcome Michael to the team," CEO Ken d'Entremont said in a statement. "Michael has extensive experience in business development and brings a successful track record of expanding product lines. Having such an experienced pharmaceutical industry professional and business leader on board will assist us in identifying in-licensing opportunities and acquisitions of new complementary assets that can leverage our North American sales force."

At Medexus, Pine will work to develop the company's product portfolio in both the US and Canada. His appointment is effective from September 21.

"Michael can make an immediate contribution to the numerous deals we are currently negotiating and will help accelerate our M&A and licensing strategy to grow revenue, increase cash flow and drive economies of scale," d'Entremont added.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

**Price:** 5.43

**Market Cap:** \$78.49 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDP

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	5.78	1.42

**Sector:** Pharma & Biotech

**Website:** [www.medexusinc.com](http://www.medexusinc.com)

### Company Synopsis:

*Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).